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Abstract
Background: Long-term sedative use is prevalent and associated with significant morbidity, including adverse
events such as falls, cognitive impairment, and sedation. The development of dependence can pose significant
challenges when discontinuation is attempted as withdrawal symptoms often develop. We conducted a scoping
review to map and characterize the literature and determine opportunities for future research regarding
deprescribing strategies for long-term benzodiazepine and Z-drug (zopiclone, zolpidem, and zaleplon) use in
community-dwelling adults.
Methods: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE, PsycINFO, CINAHL, TRIP,
and JBI Ovid databases and conducted a grey literature search. Articles discussing methods for deprescribing
benzodiazepines or Z-drugs in community-dwelling adults were selected.
Results: Following removal of duplicates, 2797 articles were reviewed for eligibility. Of these, 367 were retrieved for
full-text assessment and 139 were subsequently included for review. Seventy-four (53 %) articles were original
research, predominantly randomized controlled trials (n = 52 [37 %]), whereas 58 (42 %) were narrative reviews and
seven (5 %) were guidelines. Amongst original studies, pharmacologic strategies were the most commonly studied
intervention (n = 42 [57 %]). Additional deprescribing strategies included psychological therapies (n = 10 [14 %]),
mixed interventions (n = 12 [16 %]), and others (n = 10 [14 %]). Behaviour change interventions were commonly
combined and included enablement (n = 56 [76 %]), education (n = 36 [47 %]), and training (n = 29 [39 %]). Gradual
dose reduction was frequently a component of studies, reviews, and guidelines, but methods varied widely.
Conclusions: Approaches proposed for deprescribing benzodiazepines and Z-drugs are numerous and heterogeneous.
Current research in this area using methods such as randomized trials and meta-analyses may too narrowly encompass
potential strategies available to target this phenomenon. Realist synthesis methods would be well suited to understand
the mechanisms by which deprescribing interventions work and why they fail.
Keywords: Benzodiazepines, Z-drugs, Deprescribing, Clinical pharmacology, Behaviour change wheel, Scoping review
Background
Benzodiazepines and similar sedative hypnotics, includ-
ing zopiclone, zaleplon, and zolpidem (“Z-drugs”), are
extensively prescribed medications in the community
setting [1–7]. The annual incidence of long-term benzo-
diazepine use across North America and Europe is esti-
mated to be between 0.4 % to 6 %, with higher rates of
chronic use in patients older than 65 years [5, 8–10].
The prevalence of benzodiazepine use in adults aged 18
to 64 years has remained relatively stable over the past
decade, suggesting potential issues with long-term use
beyond what is normally indicated [3, 5, 11]. Recent data
from Canada suggest important changes in prescribing
practices. New prescriptions for benzodiazepines are de-
clining, especially in older adults, while Z-drug use has
steadily increased [5]. These trends mirror similar find-
ings from other international studies [8, 12–18].
While indicated only for short-term management of
anxiety and insomnia, reasons for acute benzodiazepine
and Z-drug therapy transforming into chronic use are
complex. Several prescriber related factors are believed
to influence this process. These factors may include the
prescriber’s attitudes toward these medications and toward
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the ‘deserving’ patient, deficits in specialized knowledge
about sedative prescribing, the clinical work environment,
conflicting patient health priorities, and the prescribing
practices of others involved in the patient’s care [19, 20].
The perceived or real inaccessibility to alternative treat-
ment modalities may further encourage the renewal of
benzodiazepine and Z-drug prescriptions in favor of initiat-
ing other interventions that are perceived as less effective
[21]. Patient factors including disagreement with appropri-
ateness of cessation, fears of symptom return, withdrawal
experiences, and the impression of unsuitability of alterna-
tives also act to promote continued use [22, 23]. Consider-
ing the highly varied contributing factors that lead to
long-term benzodiazepine and Z-drug use, deprescribing
strategies need to be flexible and acceptable to both pa-
tients and clinicians.
Deprescribing is the collaborative and supportive pro-
cess of identifying, modifying, and discontinuing ther-
apies that are no longer indicated or may be causing
harm to patients [24, 25]. Research and clinical pro-
grams for deprescribing typically focus on elderly patients
due to high rates of medication-related morbidity and
mortality, such as falls, fractures, motor vehicle collisions,
daytime sedation, and cognitive impairment [26–31]. How-
ever, stable prevalence of benzodiazepine use and in-
creasing Z-drug use in adults will also require that
best-practice deprescribing strategies in this population
be identified.
Numerous pharmacologic and nonpharmacologic de-
prescribing strategies have been reported in the litera-
ture with significant heterogeneity in the range and
scope of psychological therapies, pharmacotherapy sub-
stitution approaches, and gradual dose reduction (GDR)
schedules. We conducted a scoping review to map and
characterize the literature, identify potential research
gaps, and determine opportunities for future systematic
syntheses regarding strategies and behaviour change
interventions for deprescribing benzodiazepines and
Z-drugs in community-dwelling adults who are long-
term users (i.e., eight weeks or longer).
Methods
Scoping review methods are appropriate for our topic
area given the complexity and heterogeneity of existing
research [32]. The intention is to characterize and map
the literature, identify research gaps, and prioritize tar-
geted areas for future reviews and research [33]. We also
aimed to explicate various interventions used in the litera-
ture and characterize them according to the Behaviour
Change Wheel based on the work of Michie et al. [34].
We followed scoping review procedures slightly modified,
but as outlined by Arskey and O’Malley [35] and further
explicated by Levac et al. [32] and others [33, 36–39]. Our
review was conducted in six iterative stages including
developing the research question, identifying relevant arti-
cles, selecting articles, extracting data, collating results,
and engaging stakeholders through consultation (e.g., pre-
sentations on the topic) (Additional file 1).
Definitions and search strategies
As a research team we met and reached consensus on
population, intervention, comparator, and outcome defi-
nitions (Additional file 1). We limited our target popula-
tion to patients taking benzodiazepines and Z-drugs in
the community or outpatient settings as individuals re-
ceiving care in inpatient, long-term care, or residential
aged care facilities can differ systematically with respect
to numerous factors. These factors include, but are not
limited to, the context of the environment, frailty, nature
and number of illnesses, and treatment goals. Long-term
use was defined as regular use beyond an eight-week
period. The target medications for this review included
all benzodiazepines and Z-drugs, defined as “zopiclone”,
“eszopiclone”, “zolpidem”, or “zaleplon”.
Due to the broad nature of scoping reviews, we did
not limit our research question to a particular type of
intervention or comparator and included studies investi-
gating pharmacologic, psychological, and various mixed
methods of discontinuing benzodiazepine or Z-drug
therapy. We classified pharmacologic interventions as
those adding additional drug therapy (non-benzodiazepine
or Z-drug) to facilitate discontinuation of the sedative or
mitigate withdrawal symptoms. Psychological interven-
tions were those utilizing behavioural techniques, such as
cognitive behavioural therapy (CBT), to reduce benzodi-
azepine or Z-drug use. We categorized studies as mixed
interventions if they compared various pharmacologic,
psychological, or other interventions with each other.
GDR included employing a taper regimen or switching be-
tween sedatives to facilitate benzodiazepine or Z-drug
withdrawal. The remaining intervention types not falling
within these categories were classified as ‘other’ (i.e., letter
or brief consultation).
We collaborated with a medical science librarian to
develop search methods for each database and to iden-
tify key terms and relevant medical subject headings.
Our searches were developed to model the PICO (Popu-
lation, Intervention, Comparator, Outcome) format for
clinical questions [40].We searched PubMed, EMBASE,
PsycINFO, the Cochrane Central Register of Controlled
Trials (CENTRAL), CINAHL, and JBI Ovid databases
from inception to December 19, 2013. Systematic com-
binations of the medical subject headings “benzodiazep-
ine”, “hypnotics and sedatives”, “substance withdrawal
syndrome”, “dependency”, “sleep disorders”, and “anxiety
disorders” were used together with the keywords “hyp-
notic”, “sedative”, “zopiclone”, “eszopiclone”, “zolpidem”,
“zaleplon”, “withdraw*”, “deprescrib*”, “taper”, “stop”, and
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“discontinu*”. Search terms were translated as appropriate
for each database.
To identify further references not captured in the pub-
lished medical literature, we used relevant sections of
the Canadian Agency for Drugs and Technologies in
Health’s (CADTH) “Grey Matters: a practical search tool
for evidence-based medicine” [41] to search 69 inter-
national grey literature sources from the earliest avail-
able date through January 30, 2014. We also searched
Opengrey (SIGLE), Google Advanced, screening the first
100 results for relevance to our clinical question, and
the Turning Research Into Practice (TRIP) database for
clinical practice guidelines concerning deprescribing of
benzodiazepines and Z-drugs. Additional articles poten-
tially relevant to our objectives were identified through
reviewing reference lists of articles captured in our initial
searches and by engaging with experts and colleagues.
Study selection
We used pre-defined inclusion criteria to select articles
identified through the search strategy that were relevant
to our study objectives. We included those studies that
were published in English and investigated or discussed
methods for discontinuing benzodiazepines and sedative
hypnotics in community-dwelling individuals aged 18 years
and older. Based on our pre-determined criteria, we did
not include studies that exclusively investigated benzodi-
azepine and Z-drug use in patients with conditions other
than anxiety or insomnia disorders. We excluded studies
in animals, pediatric patients (<18 years old), and short-
term users of benzodiazepines or Z-drugs (less than eight
weeks). We did not include studies investigating non-
clinical outcomes (e.g., electroencephalography and brain
imaging studies), and articles not investigating benzodi-
azepine and Z-drug discontinuation as a primary focus.
With the exception of case-reports, case-series, and com-
mentaries, articles were not excluded based on method-
ology or publication type as we sought to identify trends
across the wide spectrum of research and publications in
the area [35]. Original investigations, research syntheses,
guidelines, and narrative review articles were all eligible
for inclusion in order to capture potential differences
amongst these publications with respect to benzodiazep-
ine and Z-drug deprescribing recommendations. Indica-
tors of study quality were broadly assessed as a means to
understand the nature of research methods used and re-
ported, but study quality was not used as an inclusion
criterion.
The list of article titles and abstracts resulting from
the database and grey literature searches were scanned
independently by two reviewers (AP and JB), who assigned
a value of “include”, “exclude”, or “assess further” to each
reference. After the initial screening phase, full-text arti-
cles were retrieved and independently assessed by AP and
JB for inclusion in the review using forms for determining
eligibility criteria. Disagreements between the two asses-
sors were discussed, and a third author (AM) was con-
sulted if agreement could not be reached.
Collating, summarizing, and reporting results
The data abstraction tool was drafted and revised through
meetings throughout the stages of the review (Additional
file 1). The standardized form was designed to capture in-
formation about the year of publication, country of origin,
study type, target medication investigated, types of inter-
ventions, GDR protocol if used, duration of intervention,
and information about the participants. Behaviour change
interventions used in original research trials were catego-
rized according to the Behaviour Change Wheel as en-
ablement (“increasing means/reducing barriers to increase
capability or opportunity”), training (“imparting skills”),
persuasion (“using communication to induce positive or
negative feelings or stimulate action”), environmental re-
structuring (“changing the physical or social context”),
modeling (“providing an example for people to aspire to”),
education (“increasing knowledge or understanding”),
incentivisation (“creating expectation of reward”), coer-
cion (“creating expectation of punishment or cost”), and
restriction (“using rules to reduce opportunity to engage
in target behaviour”) [34]. Study methodology was charac-
terized according to the Agency for Healthcare Research
and Quality’s (AHRQ) “Assessing Risk of Bias and Con-
founding in Observational Studies of Interventions or Ex-
posures: Further Development of the RTI Item Bank” [42]
with the addition of systematic reviews and narrative re-
view articles. We categorized general data regarding the
direction of effect of endpoints related to benzodiazepine
and Z-drug discontinuation as a formal evaluation of the
effect size of specific interventions is beyond the objective
of a scoping review.
Prior to beginning the abstractions, an abstraction meet-
ing was held to outline the process and model how to
characterize intervention functions to establish consis-
tency among team members. Initial articles were ab-
stracted in a group environment so that discussion could
occur surrounding issues or uncertainties regarding inter-
vention function categorization. Following the initial ab-
stractions one investigator (AP) reviewed all article
abstractions for consistency in terminology, accuracy, and
comprehensiveness. The PRISMA checklist form is pro-
vided as Additional file 2.
Results
Search
Our literature search yielded 2797 articles after dupli-
cates were removed. Review of titles and abstracts led to
retrieval of 367 full-text articles for assessment (Fig. 1).
Of these, 74 original research studies and 65 review
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articles or guidelines were included (Additional file 3)
[8, 43–180]. The absence of benzodiazepine or Z-drug
discontinuation strategies as a major focus of the inter-
vention or outcome was the most frequent reason for
excluding articles.
Description of articles
Deprescribing articles for benzodiazepines and Z-drugs
were published between 1982 and 2014 with no appar-
ent trend towards growing publications in this field over
the past 30 years (Table 1). Research was primarily con-
ducted in the United States (27 %) and United Kingdom
(24 %). Articles were published in a variety of journals
with scopes including psychiatry (n = 43 [31 %]), gen-
eral/primary care (n = 37 [27 %]), pharmacology (n = 28
[20 %]), psychology and behavioural sciences (n = 11
[8 %]), and addiction (n = 11 [8 %]). Most original re-
search studies were randomized controlled trials (RCTs)
(n = 52 [37 %]), but nearly 50 % of all included articles
were non-original research (Table 1). The majority of
studies were relatively small, with less than 100 partici-
pants in total (n = 51 [69 %]). The setting of original
research included primary care and outpatient clinics
(n = 45 [61 %]), specialty clinics (n = 14 [19 %]), and uni-
versity research units (n = 8 [11 %]), while seven studies
did not report setting details (10 %).
Amongst research trials, most (n = 36 [49 %]) investi-
gated patient populations taking benzodiazepines for
multiple reasons. Insomnia or anxiety disorders were the
primary diagnosis in 16 studies each (22 %). Fewer (n = 6
[8 %]) trials focused on patients with panic disorder. In
contrast, 57 % (n = 37) of review articles examined mixed
conditions, 11 % (n = 7) insomnia, 17 % (n = 11) anxiety
disorders, and 15 % (n = 10) panic disorders. The distribu-
tion of studies reporting a mean age of 40 to 49 years, 50
to 59 years and 60 to 69 years, was 43 % (n = 32), 18 %
(n = 13), and 19 % (n = 14), respectively. The duration of
prior benzodiazepine or Z-drug use varied widely among
studies and details concerning the length of therapy
were not reported in 41 % (n = 30). The mean duration
of benzodiazepine or Z-drug use was typically less than
a decade (n = 30 [41 %]). The majority of original trials
(n = 41 [55 %]) investigated the discontinuation of any
benzodiazepine, whereas 16 % (n = 12) examined both
benzodiazepine and Z-drug discontinuation. Only three
(4 %) of 74 original studies exclusively examined strategies
for stopping Z-drugs. The remaining studies enrolled pa-
tients only if they were taking specific benzodiazepines,
most frequently alprazolam (n = 11), diazepam (n = 7), and
lorazepam (n = 6).
The general direction of effect for the endpoint of dis-
continuation of benzodiazepine or Z-drug therapy was
Fig. 1 PRISMA flow diagram showing results of search and process of selecting articles for review
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noted for each research trial, regardless of the type of
intervention studied. Of original research studies, 41 %
(n = 30) of studies demonstrated a negative (or non-
significant) effect of the intervention being investigated.
A positive effect was demonstrated in 47 % (n = 35) of
studies, while 12 % (n = 9) of research studies did not
provide sufficient data to clearly assess the direction of
the effect (Additional file 3).
Deprescribing strategies
Pharmacologic
Among original research studies, pharmacologic inter-
ventions were the most common types of interventions
assessed for their impact on reducing benzodiazepine
and Z-drug exposure (n = 42 [57 %]) (Table 2). Thirty-
three studies investigated the addition of pharmacologic
therapies to facilitate benzodiazepine or Z-drug discontinu-
ation. Amongst these, buspirone was the most frequently
studied therapy in RCTs (n = 4) and nonrandomized con-
trolled trials (n = 3), with a total of 275 subjects. Mela-
tonin was studied in five trials, of which four were RCTs
with 244 subjects. Sixteen other additive pharmacologic
agents were studied, which included beta-adrenergic
receptor antagonists (n = 3), anti-seizure drugs such as
carbamazepine, pregabalin, and valproate (n = 5), and
antidepressants such as imipramine, paroxetine, and traz-
odone (n = 5). Other medications investigated were
ondansetron (n = 1) and progesterone (n = 1).
Gradual dose reduction
Original research investigations of pharmacologic, psy-
chological, mixed, and other interventions frequently in-
cluded GDR as a component of the discontinuation
method (60 of 74 [80 %]). However, the types of GDR
regimens employed varied dramatically among trials and
15 studies did not report details about their GDR
methods. Stabilization (i.e., establishing a consistent daily
dose) of benzodiazepine or Z-drug dose prior to the ini-
tiation of tapering was a strategy employed in 28 % of
studies. As part of the GDR regimen, 31 (42 %) trials
established flexible taper plans, which involved altering
the rate of taper based on patient symptoms. The re-
maining trials established a uniform tapering regimen
that was applied to all subjects. In 13 trials (18 %), par-
ticipants were switched to another agent, most fre-
quently diazepam (n = 10), but also Z-drugs including
zopiclone (n = 2) and zolpidem (n = 1). The time frame
over which GDR was conducted ranged from one to
more than 16 weeks with the most common (n = 11) be-
ing four weeks (median 6 weeks, interquartile range 4–8
weeks). Twenty studies employing GDR did not report
the time frame of their taper regimen. The most com-
mon taper rate among studies (n = 16) was decreasing
the original dose by 25 % weekly (i.e., 75 % of original
Table 2 Benzodiazepine and Z-drug deprescribing strategies
studied or discussed in publications
Strategies researched in original studies No. % of 74
Pharmacologic therapy 42 56.8 %
Psychological therapy 10 13.5 %
Mixed 12 16.2 %
Other 10 13.5 %
Strategies discussed in non-original articles No. % of 65
Pharmacologic therapy 24 36.9 %
Psychological therapy 30 46.2 %
GDR 60 92.3 %
Other 21 32.3 %
Table 1 Characteristics of publications on benzodiazepine and
Z-drug discontinuation in community dwelling adults
Characteristic No. % of 139 articles
Type of article
Original research
Randomized-controlled trial 52 37.4 %
Before-after study 8 5.8 %
Nonrandomized controlled trial 6 4.3 %
Systematic review/meta-analysis 3 2.2 %
Prospective cohort study 2 1.4 %
Non-comparative study 2 1.4 %
Retrospective cohort study 1 0.7 %
Non-original research
Narrative review 58 41.7 %
Guideline 7 5.0 %
Country of origin
United States 38 27.3 %
United Kingdom 33 23.7 %
Europe 24 17.3 %
Canada 20 14.4 %
Australia 13 9.4 %
Asia 2 1.4 %
Other 9 6.5 %
Year of publication
<1985 4 2.9 %
1985–1994 50 36.0 %
1995–2004 40 28.8 %
2005–2015 45 32.4 %
Primary medical condition
Mixed 73 52.5 %
Anxiety disorders 27 19.4 %
Insomnia 23 16.5 %
Panic disorders 16 11.5 %
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dose for one week, then 50 % of original dose for one
week, then 25 % of original dose for one week, then
stop). Seven studies outlined a slower approach, decreas-
ing the dose by 25 % every two to four weeks. Shorter
tapers were also reported in seven studies, with the dose
reduced by half for one to two weeks before the benzo-
diazepine or Z-drug was discontinued.
The majority of review articles and clinical practice
guidelines (60 of 65 [92 %]) recommended GDR as part
of a discontinuation strategy (Table 2). Recommendations
concerning GDR strategy varied widely but a flexible ap-
proach and substitution of a long-acting benzodiazepine
were frequent suggestions.
Psychological therapies
Psychological therapies to facilitate discontinuation of
benzodiazepines and Z-drugs were studied in 10 trials
(14 %), with 60 % of these trials utilizing CBT (Table 2).
Other strategies employed via both group and individu-
alized therapies included anxiety management, stress
management, and psychotherapy. Nine of these 10 trials
were RCTs with a total of 408 patients.
Mixed and other interventions
Mixed interventions comparing various pharmacologic,
psychological, or other interventions were the focus of
12 (16 %) studies (Table 2). Five of these 12 trials com-
pared more than two types of interventions. Common
interventions included psychological therapy (most fre-
quently CBT), GDR alone, and usual care. Other inter-
ventions that were investigated in 14 % of original
research studies included interventions such as sending
a letter or detailed information to patients and brief
counseling by clinicians.
Intervention functions
Six of the nine intervention types described by Michie
et al., [34] were used in the research studies included.
The majority of original studies included a single inter-
vention function (n = 39 [53 %]), while the remainder
combined two (n = 12 [16 %]), three (n = 21 [28 %]), or
four (n = 2 [3 %]) distinct functions (Additional file 3).
The most common method employed was enablement,
which was used in 76 % (n = 56) of studies. The major-
ity of studies using enablement techniques attempted
to achieve benzodiazepine or Z-drug cessation by test-
ing the effect of GDR, additional pharmacotherapy, or
psychological therapies. Education and training were
also frequent elements assessed by research studies, be-
ing a component of 47 % (n = 35) and 38 % (n = 28) of
studies, respectively. A total of 11 studies investigated
persuasion interventions (15 %), which frequently in-
volved the physician sending a letter to patients to ex-
plain the harms of benzodiazepines or Z-drugs and
encouraging discontinuation. Three trials tested envir-
onmental restructuring techniques to facilitate discon-
tinuation. In addition to other strategies, one trial
evaluated modeling as a component of a patient infor-
mation package [8].
Discussion
We identified 139 articles for deprescribing benzodiaze-
pines and Z-drugs in community-dwelling adults that in-
cluded a range of different strategies and behaviour
change interventions. This is in contrast to recent meta-
analyses that included 32 studies or fewer [117, 136, 138].
While meta-analyses of data can offer valuable answers
to specific research and clinical questions, the strict in-
clusion criteria based on study methodology and quality
can limit the amount of information they provide on the
research area as a whole. Research and publications that
would be characterized as lower levels of evidence in
hierarchies [181–183] (e.g., non-randomized trials, guide-
lines, narrative reviews) can be captured in scoping re-
views, which is important in many clinical questions
given the kinds of evidence that inform clinicians and pa-
tients in decision-making [184]. In our scoping review,
we included systematic reviews, individual RCTs, practice
guidelines, reviews, and other study designs to char-
acterize the literature, identify research gaps and future
research priorities, and determine opportunities for fu-
ture systematic syntheses regarding deprescribing strat-
egies. This more inclusive approach reflects the sources
of information utilized by clinicians, especially for thera-
peutic decisions that require individualized and flexible
care plans, such as benzodiazepine and Z-drug discon-
tinuation [185].
Pharmacologic interventions have been the primary
discontinuation strategy reported on in the majority of
studies within previous meta-analyses [117, 136, 138].
Likewise, our scoping review found that the addition of
pharmacologic agents to facilitate discontinuation has
been the most commonly studied type of intervention in
RCTs (31 trials, totaling 2273 patients). This method of
discontinuation may be counterintuitive to both pre-
scribers and patients as risks for different adverse events
and increased costs are inherent within this approach.
Despite the majority of trials studying this method, non-
original review articles and guidelines included in our
scoping review did not discuss this approach as fre-
quently. This is especially important to consider given
the large degree of variability and tensions that can exist
with the use of different forms of evidence in clinical
decision-making [186–188]. Depending on the practi-
tioner, guidelines and narrative reviews may be signifi-
cantly influential in decision-making. Patients will also
inherently use various forms of information about medi-
cations in their decision-making, much of which will not
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necessarily include information from clinical trials but
that is readily accessible on the internet [189].
Our review revealed that benzodiazepine and Z-drug
deprescribing interventions are numerous, largely het-
erogeneous, and poorly described. The pace of publica-
tion annually remained stable, indicating maintained
interest in this field. Estimates of effect size direction,
while not attributable to a specific intervention or inter-
vention type, were mixed with 47 % of trials being posi-
tive, 41 % negative, and 12 % undetermined, suggesting a
lack of clarity regarding how to best deprescribe benzo-
diazepines and Z-drugs. Replication of strategies in the
clinical practice setting with fidelity to interventions that
were studied is nearly impossible owing to the large
number of approaches examined and the lack of details
provided in some reports. Guidelines such as the Template
for Intervention Description and Replication (TIDieR)
[190] and the checklist by the Workgroup for Intervention
Development and Evaluation Research (WIDER) [191]
should be used to describe interventions in sufficient detail
to allow for their replication not only for subsequent re-
search but in clinical practice. It would also allow investi-
gators to better develop implementation strategies for
various interventions in a range of settings using imple-
mentation frameworks [192].
Limited theoretical underpinnings of interventions com-
bined with the significant heterogeneity and complexity of
strategies as found in our review, presents challenges in
helping to understand and explain the mechanisms by
which interventions work, why they work, for whom,
and in which contexts. Furthermore, with rising use of
Z-drugs and other psychotropics for insomnia (e.g., que-
tiapine) [193] we need to understand whether strategies
that work for benzodiazepines are in fact those that
work for discontinuing other types of hypnotics. We rec-
ommend that a realist synthesis [194] approach be used
in future syntheses given the complexity of these issues
and the need to better understand the mechanisms by
which deprescribing interventions for benzodiazepines
and Z-drugs work and why they fail [195].
The generalizability of results from available studies is
problematic due to the risk of sample distortion bias and
selection bias affecting the findings. Across several stud-
ies, subjects participated because they were already mo-
tivated to stop their benzodiazepine or Z-drug. For
many existing users, there is significant reluctance or re-
fusal to discontinue benzodiazepines and Z-drugs when
given the opportunity [22, 196, 197]. Additionally, long-
term users of benzodiazepines and Z-drugs may have
comorbidities that would exclude them from participat-
ing in many deprescribing clinical trials. The goals of
care in patients with ongoing comorbidities may be quite
different and benzodiazepine and Z-drug deprescribing
may not be an immediate priority. Participants in trials
were often of younger age (i.e., 40 to 50 years), which
does not match with the older population targeted by
deprescribing initiatives that aim to reduce harm. Re-
search in the area of deprescribing benzodiazepines and
Z-drugs should focus on older people with a wide range
of comorbidities.
To date, the outcome of interest in benzodiazepine
and Z-drug deprescribing research has largely been
whether or not treatment was successfully stopped. Clin-
ical outcomes such as impact on reducing falls, frac-
tures, quality of life, and mortality have been evaluated
less frequently [108, 198]. Future research should deter-
mine the specific harms associated with long term seda-
tive use, especially in vulnerable groups (e.g., frail adults,
patients with multiple comorbidities), and aim to identify
which patients benefit from benzodiazepine and Z-drug
discontinuation in terms of quality of life, morbidity, and
mortality.
There are limitations to this review. First, our search
may not have been exhaustive, despite the search of
multiple databases and grey literature sources. The lack
of standardized medical subject headings in the develop-
ing area of deprescribing may have partially contributed
to this. Second, we did not extract specific information
about interventions studied and reviewed within the lit-
erature to determine which strategies are optimal for fa-
cilitating benzodiazepine and Z-drug discontinuation, as
this is not the intended purpose of a scoping review.
Third, although a predefined abstraction tool and classi-
fication scheme can minimize subjectivity among ab-
stractors, there may be variability among investigators.
Conclusions
Long-term and inappropriate use of benzodiazepines
and Z-drugs remains a problem in community dwelling
adults. Numerous pharmacologic, psychological, and
other interventions have been used to support long-term
benzodiazepine and Z-drug discontinuation, yet strat-
egies are diverse and often poorly reported in sufficient
detail to allow replication in future research or clinical
practice. Using scoping review methods for this complex
problem allowed for inclusion of a greater breadth of lit-
erature and the freedom to characterize and identify
existing gaps in research, whereas traditional synthe-
ses methods restrict clinicians to mostly RCT data of
pharmacologic augmentation of GDR. Our results indi-
cate that the current research in this area using methods
such as RCTs and meta-analysis may too narrowly encom-
pass the potential strategies available to target this
phenomenon. Future studies in this area should describe
interventions in sufficient detail, including information on
various behaviour change techniques, to allow for their
replication in research and clinical practice. This process
could be facilitated by the use of standardized reporting
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guidelines and various checklists that currently exist [190,
191]. More research regarding the impact of deprescribing
strategies on patient-centered outcomes in real-word set-
tings is required. Realist synthesis methods would be well
suited to understand the mechanisms by which depre-
scribing interventions for benzodiazepines and Z-drugs
work and why they fail.
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